Letter to the Editor

A tetrahydrobiopterin deficit finding in schizophrenia: A confirmation study

Dear Editor:

Tetrahydrobiopterin (BH_4) is a vital cofactor that maintains availability of amine neurotransmitters such as dopamine and serotonin, regulates nitric oxide synthesis, and stimulates and modulates the glutamatergic system (Thony et al., 2000; Sumi-Ichinose et al., 2001). Dysregulation of these neurotransmitter systems has been implicated in the pathogenesis of schizophrenia (reviewed in Morrison and Murray, 2018). BH_4, the oxidized quinonoid dihydrobiopterin (BH_2), and biopterin constitute total biopterins in circulating blood (Thony et al., 2000). We and others have reported significantly lower fasting plasma or serum total biopterins in patients with schizophrenia (Richardson et al., 2005; Teraishi et al., 2018) and schizoaffective disorder (Richardson et al., 2007), which has been considered to likely reflect a physiologically significant BH_4 deficit due to reduced levels of CNS amine neurotransmitters (reviewed in Richardson et al., 2007). It has been hypothesized that alleviation of this deficit may prove to be a beneficial treatment approach for patients (Okusaga, 2014) and thus the aim of this current study was to confirm the presence of a BH_4 deficit in schizophrenia patients.

In a new sample of 90 patients with DSM IV schizophrenia and 65 control subjects (see Supplementary methods and results), well-matched by gender, race/ethnicity and age, we assayed fasting plasma BH_4 levels via the method of (Fekkes and Voskuilen-Kooijman, 2007, see also Supplementary methods). The *GCH1* gene encodes the first and rate-limiting enzyme in BH_4 biosynthesis, and significantly lower peripheral *GCH1* expression has been reported in patients with first-episode psychosis (Ota et al., 2014). The rs10137071 *GCH1* promotor variant (G to A allele) has also been associated with decreased gene expression and a deficit of total biopterins in patients with schizophrenia and schizoaffective disorder (Clelland et al., 2018). Thus, subjects were also genotyped for the rs10137071 promotor variant.

In our primary analysis, simple linear regression was employed to model the relationship between diagnostic group (patients versus controls) and ln (BH_4). Based upon our previous studies of total biopterins (Richardson et al., 2005; Richardson et al., 2007) and *GCH1* expression (Clelland et al., 2018), the covariates of fasting phenylalanine level, ethnicity, age, and medications found to predict peripheral expression in patients (risperidone, valproate and olanzapine), were tested in a full multivariable model and sequentially a nested model which carried forward only terms with p-values <0.05. Model fit was determined using the Likelihood ratio test and confirmed via Akaike information criterion (AIC) and Bayesian information criterion (BIC).

In both the full and nested models we observed a significant effect of diagnostic group on fasting BH_4 levels (p < 0.05). Retaining the covariate of risperidone use in the final model (LR test χ^2 (6) = 3.75, p = 0.71; AIC/BIC nested model < full model), the results indicated that schizophrenia patients had ln (BH_4) levels on average 22% lower than control subjects (Fig. 1, n = 155, p < 0.05). A stratified analysis, excluding all patients receiving risperidone, replicated the model finding. Analysis of total biopterins as the dependent variable in an analogous full model also revealed as anticipated, lower fasting plasma levels in the schizophrenia patients as compared to the control group, however the effect did not reach two-tailed significance (n = 155, β = −2.686, t_{146} = −1.81, 1-tailed p = 0.036), possibly due to the smaller numbers investigated here than in previous studies of total biopterins (Richardson et al., 2005; Teraishi et al., 2018).

We previously observed a significant linear relationship between total biopterins and *GCH1* genotype in patients (Clelland et al., 2018), and thus in a secondary analysis (due to multicollinearity of predictor variables), we investigated the relationship between fasting plasma ln (BH_4) and the three level ordinal genotype by diagnostic group: controls (n = 65), GG patients (n = 26), A allele patients (n = 64). There was a significant linear relationship (β = −0.194, t_{152} = −2.05, p = 0.042), and interpretation of the β coefficient indicates that there is on average a 19% lower ln (BH_4) between each level, following adjustment for risperidone use; schizophrenia patients with the variant A allele (AA and GA genotypes) having BH_4 levels lower than GG patients, who had ln (BH_4) lower than controls (Supplementary Fig. S1).

In summary, previous studies of circulating total biopterins have pointed to the presence of lower fasting BH_4 levels in schizophrenia patients. We now show a significant BH_4 deficit in a new sample of patients compared to a matched control subject group. The results of this study provide further support for research into therapeutics for alleviating the BH_4 deficit, which may be particularly beneficial in patients carrying the variant allele.

Funding

Contributors

Concept and design: Dr. James D. Clelland (JDC) and Dr. Catherine L. Clelland (CLC). Acquisition of human samples and data: JDC, Dr. Jennifer Smeed, Dr. Serge Cremers, and CLC. Statistical analysis and interpretation of results: JDC and CLC. Writing of the manuscript: JDC and CLC. All authors contributed to and have approved the manuscript.

Fig. 1. BH$_4$ levels are significantly lower in patients with schizophrenia. In the fitted model ($F_{2,152}$ = 3.16, p = 0.045) there was a significant effect of diagnostic group on fasting plasma ln (BH$_4$) (β = −0.38, t_{152} = −2.15, *p = 0.033), following adjustment for risperidone use (yes, no). Schizophrenia patients (n = 90, adjusted mean = 1.34, standard error = 0.11) had on average BH$_4$ levels 22% lower than controls (n = 65, adjusted mean = 1.73, standard error = 0.13). Following a stratified analysis which excluded patients receiving risperidone (n = 36), the significant effect of diagnostic group remained (β = −0.38, t_{117} = −2.03, p = 0.045). Means (ln) are plotted for each diagnostic group, with SEM's represented by the internal box (red) within each bar. Individual subject points are depicted by black jittered dots for controls and GG patients, and green triangles for A allele patients (AA and GA genotypes). Statistical analyses were conducted using STATA v14.2 (College Station, TX).

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.schres.2019.06.006.

References

Clelland, J.D., Read, L.L., Smeed, J., Clelland, C.L., 2018. Regulation of cortical and peripheral GCH1 expression and biopterin levels in schizophrenia-spectrum disorders. Psychiatry Res. 262, 229–236.

Fekkes, D., Voskuilen-Kooijman, A., 2007. Quantitation of total biopterin and tetrahydrobiopterin in plasma. Clin. Biochem. 40 (5–6), 411–413.

Morrison, P.D., Murray, R.M., 2018. The antipsychotic landscape: dopamine and beyond. Ther Adv Psychopharmacol 8 (4), 127–135.

Okusaga, O.O., 2014. 6R-l-erythro-5,6,7,8-tetrahydrobiopterin (BH4): a potential treatment for all symptom domains of schizophrenia. Med. Hypotheses 82 (3), 395–397.

Ota, V.K., Noto, C., Gadelha, A., Santoro, M.L., Spindola, L.M., Gouvea, E.S., Stilhano, R.S., Ortiz, B.B., Silva, P.N., Sato, J.R., Han, S.W., Cordeiro, Q., Bressan, R.A., Belangero, S.I.,

2014. Changes in gene expression and methylation in the blood of patients with first-episode psychosis. Schizophr. Res. 159 (2–3), 358–364.

Richardson, M.A., Read, L.L., Taylor Clelland, C.L., Reilly, M.A., Chao, H.M., Guynn, R.W., Suckow, R.F., Clelland, J.D., 2005. Evidence for a tetrahydrobiopterin deficit in schizophrenia. Neuropsychobiology 52 (4), 190–201.

Richardson, M.A., Read, L.L., Reilly, M.A., Clelland, J.D., Clelland, C.L., 2007. Analysis of plasma biopterin levels in psychiatric disorders suggests a common BH4 deficit in schizophrenia and schizoaffective disorder. Neurochem. Res. 32 (1), 107–113.

Sumi-Ichinose, C., Urano, F., Kuroda, R., Ohye, T., Kojima, M., Tazawa, M., Shiraishi, H., Hagino, Y., Nagatsu, T., Nomura, T., Ichinose, H., 2001. Catecholamines and serotonin are differently regulated by tetrahydrobiopterin. A study from 6-pyruvoyltetrahydropterin synthase knockout mice. J. Biol. Chem. 276 (44), 41150–41160.

Teraishi, T., Kajiwara, M., Hori, H., Sasayama, D., Hidese, S., Matsuo, J., Ishida, I., Kajiwara, Y., Ozeki, Y., Ota, M., Hattori, K., Higuchi, T., Kunugi, H., 2018. 13C-phenylalanine breath test and serum biopterin in schizophrenia, bipolar disorder and major depressive disorder. J. Psychiatr. Res. 99, 142–150.

Thony, B., Auerbach, G., Blau, N., 2000. Tetrahydrobiopterin biosynthesis, regeneration and functions. Biochem. J. 347 (Pt 1), 1–16.

James D. Clelland
Clinical Research Department, The Nathan S. Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY, United States of America
Department of Psychiatry, New York University Langone Medical Center (NYU), 550 First Avenue, New York, NY, United States of America

Jennifer Smeed
Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, 630 West 168th Street, New York, NY, United States of America

Serge Cremers
Department of Pathology and Cell Biology, Columbia University Medical Center, 630 West 168th Street, New York, NY, United States of America

Catherine L. Clelland

Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, 630 West 168th Street, New York, NY, United States of America

Department of Pathology and Cell Biology, Columbia University Medical Center, 630 West 168th Street, New York, NY, United States of America

Corresponding author at: Department of Pathology and Cell Biology, Columbia University Medical Center, 630 West 168th Street, P&S 12-461A, New York, NY 10032, United States of America.

E-mail address: cc2786@cumc.columbia.edu

31 May 2019